Articles tagged with: screening

05
August
2013

Prostate Cancer World Congress in Melbourne

Prostate Cancer World Congress in Melbourne

This week sees the Prostate Cancer World Congress meeting in Melbourne, from 7th to 9th August.

The meeting brings together experts in prostate cancer management to discuss latest developments in basic science understanding of prostate cancer, PSA testing and screening, active surveillance and prostate cancer treatment.

International experts Thomas Ahlering, William Catalona, and Patrick Walsh will join many other faculty in delivering a packed program.

Adelaide Urologists Nick Brook and Denby Steele will be attending. Follow @nickbrookMD on twitter, or following the twitter hashtag #PCWC13 for live updates of the conference.

Categories: Prostate Cancer

24
July
2013

International Experts come to Sydney to Discuss Lower Urinary Tract Symptoms

International Experts come to Sydney to Discuss Lower Urinary Tract Symptoms

The Urological Society of Australia and New Zealand held the 2nd Symposium on Male Lower Urinary Tract Symptoms, in Sydney on 21st July.

Henry Woo and Peter Gilling convened the meeting, and international experts Prof. Alan Wein and Prof. Kevin McVary were invited speakers.

Nick Brook co-chaired the OAB session by Alan Wein (see picture).

Topics discussed included latest developments in overactive bladder, underactive bladder, and the treatment of male lower urinary tract problems.

Newer treatments were disussed, including the Greenlight and Holmium lasers, and there was presentation of some potential developments for the future, including:

  1. Aquablation
  2. Rezum, and
  3. Urolift

The meeting provided insight into some exciting basic science and clinical research in this important area of urology.

Categories: Updates

12
July
2013

Omega-3 Fish Oils Linked to Increased Prostate Cancer Risk

Omega-3 Fish Oils Linked to Increased Prostate Cancer Risk

A large study by researchers in Seattle, USA has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer.

Published in the online edition of the Journal of the National Cancer Institute, the findings indicate that high concentrations of three of the fatty acids found in fatty fish and fish-oil supplements are associated with an increased risk of prostate cancer.

This study looked at previously collected data from the SELECT investigation, a large research project that found selenium and vitamin E were not beneficial in reducing prostate cancer risk.

The latest study found that in men taking omega-3 supplementation, there was a:

  1. 43 percent increase in risk for all prostate cancers
  2. 71 percent increase in the risk of high-grade prostate cancer
  3. 44 percent increase risk of low-grade prostate cancer

The increase in risk for high-grade prostate cancer is important because such tumours are more likely to be fatal.

Two other studies reported similar findings, one was from the same centre in 2011 and the other from a large European study. Furthermore, an analysis of 20 studies on the effect of fish oils on cardiovascular risk, published in the Journal of the American Medical Association, found that there was no reduction in stroke or heart attack risk in patients taking fish oil supplements.

What the study doesn’t answer:

  1. It doesn’t explain how this effect occurs
  2. It doesn’t make clear what the effect of taking fish oils is in men who already have a diagnosis of prostate cancer.

The fact that these large studies have drawn similar conclusions does now mean that individuals taking these supplements should carefully consider the risks.

The reference for the study is: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial. Journal of the National Cancer Institute, 2013. Published online July 11 2013


Categories: Updates, Prostate Cancer

13
June
2013

Agent Orange linked to aggressive prostate cancer in Vietnam Veterans

Agent Orange linked to aggressive prostate cancer in Vietnam Veterans

Agent Orange was one of the herbicides and defoliants used by the U.S. military during the Vietnam War from 1961 to 1971.

A 50:50 mixture of 2,4-dichlorophenoxyacetic acid and 2,4,5-trichlorophenoxyacetic acid, Agent Orange was later found to be contaminated with 2,3,7,8-tetrachlorodibenzodioxin, a highly toxic dioxin.

This combination of agents has been linked to a number of serious negative health effects, which are well known.

Garzotto and co-researchers from the Portland Veterans Administration Medical Centre, and Oregon Health and Science University, have published a study linking Agent Orange to an increased risk of high-grade prostate cancer.

Analysis revealed that:

  1. Overall rates of prostate cancer were increased in veterans exposed to Agent Orange
  2. Agent Orange exposure was linked to a 52% increase in overall risk of prostate cancer detection by biopsy.
  3. The risk of a higher-grade cancer (a Gleason score of 8 or higher) in men exposed to Agent Orange increased 110% over men who were not exposed.

The study’s authors suggest that information about Agent Orange exposure has the potential to improve prostate cancer screening for Veterans. If there is a history of exposure to Agent Orange, this could prompt screening and earlier detection, which has the potential to prolong survival and improve quality of life for patients.

The Study has been published online in the journal ‘Cancer’

Link
Cancer - online

Categories: Prostate Cancer

Affiliations

Urology Affiliations

Latest Tweets

Contact Us

  • Nick Brook Urology
    Calvary North Adelaide Hospital
    89 Strangways Tce,
    North Adelaide,
    Adelaide SA 5006
  • 08 8267 1424
  • 08 8267 1370